Physical birth outcomes in neonates prenatally exposed to buprenorphine – our first experiences
Journal
Srpski Arhiv za Celokupno Lekarstvo
Date Issued
2019-09-17
Author(s)
DOI
https://doi.org/10.2298/SARH171213105S
Abstract
Introduction/Objective Buprenorphine appears generally similar to, and in some cases superior to,
methadone in terms of maternal, fetal, and neonatal outcomes.
The objective of the study was to assess some physical birth outcomes in neonates prenatally exposed
to buprenorphine.
Methods During a seven-year period, nine patients have been treated with buprenorphine during their
pregnancy. All women underwent interview, clinical investigations, biochemical analysis, toxicological
screening, viral markers for hepatitis B, C, HIV, with regular check-ups by an obstetrician and a psychiatrist.
Newborn outcomes included: birth weight in grams, birth length in centimeters, physical anomalies,
head/chest circumference in centimeters, Apgar score at 1 minute / 5 minutes, gestational age (weeks),
newborn length of hospital stay in days, breast-feeding, the newborn’s need for pharmacologic treatment after delivery.
Results The mean birth weight was 2,991.11 ± 37 g; birth length was 49.44 ± 2.29 cm; head circumference
was 33.11 ± 0.78 cm; chest circumference was 32.33 ± 1 cm; first minute Apgar score was 8.22, fifth minute
9.22; age at delivery was 38.77 ± 1.09 weeks; hospitalization after delivery 4.44 ± 1.13 days. None of the
newborns had physical anomalies. Six of the newborns were breastfed.
Conclusion Buprenorphine is a safe and important part of a complete comprehensive treatment approach
in pregnant women with opioid use disorder. Buprenorphine treatment of maternal opioid use disorder
indicated a low risk of preterm birth, normal birth weight and length, head and chest circumference,
Apgar score, short hospitalization after delivery.
methadone in terms of maternal, fetal, and neonatal outcomes.
The objective of the study was to assess some physical birth outcomes in neonates prenatally exposed
to buprenorphine.
Methods During a seven-year period, nine patients have been treated with buprenorphine during their
pregnancy. All women underwent interview, clinical investigations, biochemical analysis, toxicological
screening, viral markers for hepatitis B, C, HIV, with regular check-ups by an obstetrician and a psychiatrist.
Newborn outcomes included: birth weight in grams, birth length in centimeters, physical anomalies,
head/chest circumference in centimeters, Apgar score at 1 minute / 5 minutes, gestational age (weeks),
newborn length of hospital stay in days, breast-feeding, the newborn’s need for pharmacologic treatment after delivery.
Results The mean birth weight was 2,991.11 ± 37 g; birth length was 49.44 ± 2.29 cm; head circumference
was 33.11 ± 0.78 cm; chest circumference was 32.33 ± 1 cm; first minute Apgar score was 8.22, fifth minute
9.22; age at delivery was 38.77 ± 1.09 weeks; hospitalization after delivery 4.44 ± 1.13 days. None of the
newborns had physical anomalies. Six of the newborns were breastfed.
Conclusion Buprenorphine is a safe and important part of a complete comprehensive treatment approach
in pregnant women with opioid use disorder. Buprenorphine treatment of maternal opioid use disorder
indicated a low risk of preterm birth, normal birth weight and length, head and chest circumference,
Apgar score, short hospitalization after delivery.
File(s)![Thumbnail Image]()
Loading...
Name
Buprenorfin cjelokupno ljekarstvo 2019.pdf
Size
162.15 KB
Format
Adobe PDF
Checksum
(MD5):dc8d97b571813f08f7572124ae9f835d